Sanofi on Thursday said it was expecting earnings per share to grow around 5 percent at constant exchange rates in 2020, weeks after pledging to focus on vaccines and key treatments like its eczema medicine Dupixent until 2022.
Sanofi eyes more growth this year as it narrows focus
